Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2023

Open Access 19-08-2023 | Osteosarcoma | Translational Research

LncRNA EBLN3P Facilitates Osteosarcoma Metastasis by Enhancing Annexin A3 mRNA Stability and Recruiting HuR

Authors: Shengtao Wang, MM, Xinxin Zeng, MM, Peng Gui, MM, Shujuan Xu, MM, Zhaoxu Li, MD, Dongxu Chen, MM

Published in: Annals of Surgical Oncology | Issue 13/2023

Login to get access

Abstract

Background

Osteosarcoma (OS) represents a common type of bone cancer. Long non-coding RNAs (LncRNAs) have shown their potential in therapeutic modalities for OS. This study’s purpose was to reveal the action of lncRNA EBLN3P on OS growth and metastasis and its mechanism.

Methods

Expressions of EBLN3P/Hu antigen R (HuR)/Annexin A3 (ANXA3) were determined by RT-qPCR/Western blot. Proliferation/migration/invasion of OS cells were assessed via CCK-8/Transwell assays after interfering EBLN3P/ANXA3/HuR. The co-localization of EBLN3P/ANXA3/HuR cells was observed by FISH/immunofluorescence assays. Interplays among EBLN3P/ANXA3/HuR and the half-life period of ANXA3 were assessed by RNA immunoprecipitation/RNA pull-down/RNA stability experiment. The nude mouse xenograft model was established, followed by EBLN3P treatment to assess the function of EBLN3P on OS.

Results

EBLN3P/ANXA3 was highly expressed in OS cells. Silencing EBLN3P or ANXA3 limited the proliferation/migration/invasion of OS cells. Mechanically, EBLN3P/ANXA3 can bind to HuR, and EBLN3P enhanced ANXA3 mRNA stability by recruiting HuR, thus facilitating OS cell growth. Upregulated HuR or ANXA3 counteracted the suppressive action of silencing EBLN3P on OS cells. In vivo experiments revealed facilitated tumor growth and metastasis in vivo fomented by EBLN3P through manipulation of HuR/ANXA3.

Conclusions

EBLN3P enhanced proliferative/migrative/invasive potentials of OS cells via increasing ANXA3 mRNA stability and protein level by recruiting HuR, which provided new potential therapeutic targets for OS clinical treatment. EBLN3P and ANXA3 might have potential roles in OS diagnosis, treatment, and prognosis. This study provided a theoretical reference for further clinical research in tumor surgery.
Appendix
Available only for authorised users
Literature
1.
Biazzo A, De Paolis M. Multidisciplinary approach to osteosarcoma. Acta Orthop Belg. 2016;82(4):690–8.PubMed
2.
Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722–35.CrossRefPubMed
3.
Konig M, Osnes TA, Lobmaier I, et al. Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years. Neurosurg Rev. 2017;40(3):449–60.CrossRefPubMed
4.
Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 2016;16(5):543–56.CrossRefPubMed
5.
Fu D, Lu C, Qu X, et al. LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis. Aging (Albany NY). 2019;11(19):8374–85.CrossRefPubMed
6.
Zeng X, Wang S, Gui P, Wu H, Li Z. Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS. Mol Med Rep. 2019;20(3):2583–90.PubMedPubMedCentral
7.
Bhuvaneshwar K, Harris M, Gusev Y, et al. Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients. BMC Cancer. 2019;19(1):357.CrossRefPubMedPubMedCentral
8.
Wang JY, Yang Y, Ma Y, et al. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma. Biomed Pharmacother. 2020;121:109627.CrossRefPubMed
9.
Wu J, Chen L, Zheng C, Xu S, Gao Y, Wang J. Co-expression network analysis revealing the potential regulatory roles of lncRNAs in Alzheimer’s disease. Interdiscip Sci. 2019;11(4):645–54.CrossRefPubMed
10.
Dai S, Li N, Zhou M, et al. LncRNA EBLN3P promotes the progression of osteosarcoma through modifying the miR-224-5p/Rab10 signaling axis. Sci Rep. 2021;11(1):1992.CrossRefPubMedPubMedCentral
11.
Li H, Wang M, Zhou H, Lu S, Zhang B. Long noncoding RNA EBLN3P promotes the progression of liver cancer via alteration of microRNA-144-3p/DOCK4 signal. Cancer Manag Res. 2020;12:9339–49.CrossRefPubMedPubMedCentral
12.
Xu XH, Song W, Li JH, et al. Long non-coding RNA EBLN3P regulates UHMK1 expression by sponging miR-323a-3p and promotes colorectal cancer progression. Front Med (Lausanne). 2021;8:651600.CrossRefPubMed
13.
14.
15.
Romeo C, Weber MC, Zarei M, et al. HuR Contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells. Mol Cancer Res. 2016;14(7):599–611.CrossRefPubMedPubMedCentral
16.
Li J, Dong W, Jiang Q, Zhang F, Dong H. LINC00668 cooperated with HuR dependent upregulation of PKN2 to facilitate gastric cancer metastasis. Cancer Biol Ther. 2021;22(4):311–23.CrossRefPubMedPubMedCentral
17.
Li Z, Wang Y, Hu R, Xu R, Xu W. LncRNA B4GALT1-AS1 recruits HuR to promote osteosarcoma cells stemness and migration via enhancing YAP transcriptional activity. Cell Prolif. 2018;51(6):e12504.CrossRefPubMedPubMedCentral
18.
Perron B, Lewit-Bentley A, Geny B, Russo-Marie F. Can enzymatic activity, or otherwise, be inferred from structural studies of annexin III? J Biol Chem. 1997;272(17):11321–6.CrossRefPubMed
19.
Grewal T, Rentero C, Enrich C, Wahba M, Raabe CA, Rescher U. Annexin animal models-from fundamental principles to translational research. Int J Mol Sci. 2021;22(7):3349.CrossRef
20.
Hamelin-Peyron C, Vlaeminck-Guillem V, Haidous H, et al. Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability. Clin Biochem. 2014;47(10–11):901–8.CrossRefPubMed
21.
Liu YF, Xiao ZQ, Li MX, et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 2009;217(1):54–64.CrossRefPubMed
22.
Tong M, Fung TM, Luk ST, et al. ANXA3/JNK Signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma. Stem Cell Rep. 2015;5(1):45–59.CrossRef
23.
Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol. 2008;216(2):131–40.CrossRefPubMed
24.
Zhang T, Beeharry MK, Zheng Y, et al. Long noncoding RNA SNHG12 promotes gastric cancer proliferation by binding to HuR and stabilizing YWHAZ expression through the AKT/GSK-3beta pathway. Front Oncol. 2021;11:645832.CrossRefPubMedPubMedCentral
25.
Zhou N, Li S, Wu D, Zhang F, Tang F, Li Y. The lncRNA VPS9D1-AS1 promotes hepatocellular carcinoma cell cycle progression by regulating the HuR/CDK4 Axis. DNA Cell Biol. 2021;40(10):1278–89.CrossRefPubMed
26.
Priyanka P, Sharma M, Das S, Saxena S. The lncRNA HMS recruits RNA-binding protein HuR to stabilize the 3’-UTR of HOXC10 mRNA. J Biol Chem. 2021;297(2):100997.CrossRefPubMedPubMedCentral
27.
28.
Mathias C, Muzzi JCD, Antunes BB, Gradia DF, Castro MAA, Carvalho de Oliveira J. Unraveling immune-related lncRNAs in breast cancer molecular subtypes. Front Oncol. 2021;11:692170.CrossRefPubMedPubMedCentral
29.
Ye ZM, Peng LR. Expression of Annexin A3 in osteoblasts and osteosarcoma hos cells. J Biol Regul Homeost Agents. 2020;34(1):151–6.PubMed
30.
Zhou T, Li Y, Yang L, Liu L, Ju Y, Li C. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells. Oncol Rep. 2017;37(1):388–98.CrossRefPubMed
31.
Yu SY, Li Y, Fan LQ, Zhao Q, Tan BB, Liu Y. Impact of Annexin A3 expression in gastric cancer cells. Neoplasma. 2014;61(3):257–64.CrossRefPubMed
32.
Yuan JB, Gu L, Chen L, Yin Y, Fan BY. Annexin A8 regulated by lncRNA-TUG1/miR-140-3p axis promotes bladder cancer progression and metastasis. Mol Ther Oncolyt. 2021;22:36–51.CrossRef
33.
Liu Y, Zhang Y, Zhang J, et al. Silencing of HuR inhibits osteosarcoma cell epithelial-mesenchymal transition via AGO2 in association with long non-coding RNA XIST. Front Oncol. 2021;11:601982.CrossRefPubMedPubMedCentral
34.
Xu J, Yang B, Wang L, et al. LncRNA BBOX1-AS1 upregulates HOXC6 expression through miR-361-3p and HuR to drive cervical cancer progression. Cell Prolif. 2020;53(7):e12823.CrossRefPubMedPubMedCentral
35.
Chang YZ, Chai RC, Pang B, et al. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-kappaB to promote the malignant progression of IDH-wildtype glioma. Cancer Lett. 2021;511:36–46.CrossRefPubMed
36.
Wang X, Yin J. The biological function of the long non-coding RNA endogenous born avirus-like nucleoprotein in lung adenocarcinoma is mediated through the microRNA-655-3p/B-cell lymphoma-2 axis. Bioengineered. 2022;13(4):10679–90.CrossRefPubMedPubMedCentral
37.
Yang J, Yang Y. Long noncoding RNA endogenous bornavirus-like nucleoprotein acts as an oncogene by regulating microRNA-655-3p expression in T-cell acute lymphoblastic leukemia. Bioengineered. 2022;13(3):6409–19.CrossRefPubMedPubMedCentral
38.
Majumder M, Chakraborty P, Mohan S, Mehrotra S, Palanisamy V. HuR as a molecular target for cancer therapeutics and immune-related disorders. Adv Drug Deliv Rev. 2022;188:114442.CrossRefPubMed
39.
Chang SH, Hla T. Post-transcriptional gene regulation by HuR and microRNAs in angiogenesis. Curr Opin Hematol. 2014;21(3):235–40.CrossRefPubMed
40.
Pan W, Pang J, Ji B, et al. RNA binding protein HuR promotes osteosarcoma cell progression via suppressing the miR-142-3p/HMGA1 axis. Oncol Lett. 2018;16(2):1475–82.PubMedPubMedCentral
41.
Xu W, Chen C, Xu R, et al. Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents. Biomed Pharmacother. 2018;102:587–93.CrossRefPubMed
Metadata
Title
LncRNA EBLN3P Facilitates Osteosarcoma Metastasis by Enhancing Annexin A3 mRNA Stability and Recruiting HuR
Authors
Shengtao Wang, MM
Xinxin Zeng, MM
Peng Gui, MM
Shujuan Xu, MM
Zhaoxu Li, MD
Dongxu Chen, MM
Publication date
19-08-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14032-y

Other articles of this Issue 13/2023

Annals of Surgical Oncology 13/2023 Go to the issue

ASO Research Letter

Evaluation of Content Quality for Patients Searching YouTube for Videos on Cytoreductive Surgery and Hyperthermic Intraperitoneal Peritoneal Surgery

ASO Author Reflections

ASO Author Reflections: Localized Synchronous and Metachronous Peritoneal Metastases from Colorectal Cancer—Are They Candidates for Radical Resection?

Breast Oncology

Spare the Nipple: A Systematic Review of Tumor Nipple-Distance and Oncologic Outcomes in Nipple-Sparing Mastectomy

Hepatobiliary Tumors

Annals of Surgical Oncology Practice Guidelines Series: Management of Primary Liver and Biliary Tract Cancers

Breast Oncology

Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes

ASO Author Reflections

ASO Author Reflections: Enhancing Palliative Care Delivery: The Potential of Multi-Disciplinary Intervention Teams for Surgical Oncology Patients